Alon Harris - research works

Mean age was 79.2 (SD 3.9) years; 42.4% were female.

GAT-IOP was associated with central corneal thickness (CCT) (95% CI, 0.009-0.022; p=0.02), whereas IOPcc was not (95% CI, -0.001 to 0.016; p=0.08).

AUCs were similar (0.818 vs 0.780; p=0.31).

In multivariable models, IOP measures were independently associated with glaucoma, with stronger effect size for GAT-IOP (OR=1.264; 95% CI, 1.182-1.359) than for IOPcc (OR=1.176; 95% CI, 1.116-1.241); pseudoexfoliation, family history, and body mass index were significant in both models, whereas CCT and axial length were significant only in the GAT-IOP model.

IOP values obtained by DCT and GAT showed a strong positive correlation in patients with OAG (r=0.93; P<0.001).

Mean IOP measured with DCT [18.4 (5.1) mm Hg] was significantly higher (P<0.001) than GAT IOP measurements [16.5 (4.5) mmHg].

The Bland-Altman data showed that the amount of disagreement between IOP assessment techniques varied, suggesting a proportional bias.

Mean baseline IOP was 16.5 ± 3.4 mmHg.

Adjunctive dorzolamide therapy significantly decreased vascular resistance in the ophthalmic artery (p = 0.02).

Mean diastolic BP and OPP were significantly lower after adjunctive therapy.

There were no changes in retinal microcirculation between the two phases of treatment.

The mean baseline IOP was 14.8 ± 3.5 mm Hg.

Mean IOP following bimatoprost monotherapy (12.8 ± 2.9 mm Hg) and after 2 months of dorzolamide adjunctive therapy (12.2 ± 2.6 mm Hg) were not statistically significantly different (p=0.544).

Only at the 4:00 h time point was IOP significantly reduced using the bimatoprost/dorzolamide combined treatment (p=0.013).

Repeated analysis of variance detected a significant decrease of vascular resistance in the OA (p=0.0167) with adjunctive dorzolamide treatment.

No statistically significant differences in visual field or nerve fiber layer thickness were observed between the treatment groups during 12 months of therapy.

Mean increase over 1 year of treatment in ocular perfusion and diastolic perfusion pressures were 10.46% and 10.67% in the DTFC group and 7.47% and 5.61% in the LTFC group, respectively.

OA resistive index (RI) and SPCA RI were significantly different at the 12 months visit between the two treatment groups (p=0.05 and p=0.000, respectively): DTFC treatment showed decrease in the RI.

The average number of bevacizumab injections was 6.8 injections/year.